Loading...

Alphamab Oncology

9966.HKHKSE
Healthcare
Biotechnology
HK$8.03
HK$0.00(0.00%)

Alphamab Oncology 9966.HK Peers

See (9966.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
9966.HKHK$8.03+0.00%8B43.68HK$0.19N/A
1801.HKHK$86.20+0.00%147.2B-1485.00-HK$0.06N/A
9926.HKHK$126.00+0.00%125.1B-214.62-HK$0.65N/A
1177.HKHK$6.44+0.00%122B62.00HK$0.11+1.03%
2269.HKHK$27.20+0.00%115.1B33.29HK$0.85N/A
1530.HKHK$27.95+0.00%72.2B29.42HK$1.04+0.82%
3759.HKHK$17.74+0.00%47.5B16.03HK$1.15+1.19%
9995.HKHK$68.60+0.00%44.4B-23.06-HK$2.99N/A
1877.HKHK$24.70+0.00%41B-17.68-HK$1.42N/A
6821.HKHK$90.90+0.00%37.7B28.65HK$3.26+1.29%
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

9966.HK vs 1801.HK Comparison

9966.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9966.HK stands at 8B. In comparison, 1801.HK has a market cap of 147.2B. Regarding current trading prices, 9966.HK is priced at HK$8.03, while 1801.HK trades at HK$86.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9966.HK currently has a P/E ratio of 43.68, whereas 1801.HK's P/E ratio is -1485.00. In terms of profitability, 9966.HK's ROE is +0.10%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 9966.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 9966.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;